Why Novo Nordisk A/S (NVO) Surged on Friday
We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other firms. Ten companies finished firmer on Friday,
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.
Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.
Is Novo Nordisk (NVO) the Best Stock to Buy and Hold for 2025?
We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best stocks to buy and hold for 2025.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people.
Pharma Stock Pops on Upbeat Obesity Drug Trial Results
Novo Nordisk A/S (NYSE:NVO) today announced positive early-stage trial results for its amycretin obesity drug. The treatment, which overweight and obese patients used once a week, resulted in 22% weigh reduction.
STAT2d
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
Birmingham sues drug companies, says city hurt by ‘insulin pricing scheme’
Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.
Michigan Advance3d
Unions file suit against drug middlemen, insulin makers on behalf of thousands
Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.